Articles tagged with Drug Development
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
Researchers found that dexamethasone reduces infection-driven macrophage metabolic activity and lowers inflammatory signals, preserving the immune system's ability to control the infection. This study suggests a new approach for managing nontuberculous mycobacterial disease.
The new integrations provide enterprise AI agents direct access to live, structured research data from Dimensions' 430M+ interconnected records. This allows for AI-assisted analytics across one of the world's most comprehensive linked views of global research activity.
Researchers have uncovered a key mechanism explaining how allergic inflammation in the skin can progress to a body-wide allergic response. IL-13 acts on dendritic cells, enhancing their ability to present allergens and promoting immune responses that produce antibodies.
Researchers have found a new compound that promotes joint health and reduces inflammation-related genes in a model of osteoarthritis. The drug, M04, has shown promise as an innovative OA therapy by slowing down the disease process, giving people more years of pain-free living.
Tirzepatide has been shown to reduce the risk of heart attacks and hospitalizations due to infections in people with type 2 diabetes and obesity. The study found a relative risk reduction of about one-third, corresponding to a 36% reduced risk of infection-related hospitalization.
Researchers created nearly 700 new cancer models derived from patient tumors to aid in drug development. The models, representing 25 types of cancer, are now available for global use, providing a resource for identifying new drug targets and testing potential treatments.
Researchers at the University of Manchester have developed a new family of antifungal agents that are more potent and less toxic than existing treatments. The compounds, which were discovered through genome mining, showed increased antifungal activity and improved solubility compared to existing drugs.
A new study reveals that photoreceptors possess an internal recycling system that removes damaged proteins and maintains cellular health. This discovery has important implications for inherited retinal diseases and raises questions about the safety of certain drugs in clinical testing.
Revolver Therapeutics, a spin-out company from the University of Bath, has won the Health category of the Royal Society of Chemistry's Emerging Technologies Competition with its proprietary discovery platform. The platform generates and tests millions of constrained peptide drug candidates directly inside living cells, selecting for mo...
A new peptide derived from cone snail venom has been shown to significantly reduce inflammation-induced pain in an animal model. The peptide specifically inhibits the noradrenaline transporter, supporting the body's own pain-inhibiting mechanisms.
Researchers have identified a widespread source of error in a popular genome study method and created a machine-learning tool to correct it. PATTY uses machine learning to reduce artifacts while preserving real signals in noisy data, giving researchers a clearer view of gene activity control.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
OYE Therapeutics announced positive Phase 1 results for OYE-101, a proprietary intravenous caffeine formulation. The study demonstrated the safety and tolerability of OYE-101 in healthy adult volunteers, supporting its planned development as a treatment to support emergence from general anesthesia and deep sedation.
A novel therapy targeting the bone marrow microenvironment is shown to accelerate recovery and promote hematopoietic regeneration after injury. Pharmacological activation of YAP/TAZ improves BM niche recovery, enhancing engraftment and white blood cell recovery following HSCT.
Researchers developed a new method using blue LED lights and commercial chemical building blocks to modify two carbon atoms in a single reaction, increasing the complexity of molecules quickly. This approach could lead to faster production of complex drugs with specific properties.
Deep learning models accelerate drug design, predict chemical interactions, and engineer stable candidates. AI-powered simulations optimize dosimetry, predicting biodistribution and generating patient-specific digital twins for individualized treatment planning.
Macrophages are critical drivers of chronic allograft failure, with emerging strategies targeting key macrophage signaling pathways providing an important conceptual shift. Targeted therapies, such as inhibiting the purinergic pathway and mTOR/NF-κB pathway, show promise in preventing chronic rejection.
A Wisconsin lab advance has developed a way to remove liquid chromatography from peptide mapping, an essential test for determining a candidate drug's stability. This technique accelerates the process by 100-fold, allowing companies to analyze massive data influx instantly and reducing costs.
Researchers discovered a potential drug developed at Michigan Medicine reverses metabolic dysfunction-associated steatohepatitis (MASH) in animal models by disrupting the disease-driving pathway that links the gut and liver. DT-109 improved gut health, reducing inflammation in livers of nonhuman primates.
Researchers have identified a promising drug to treat neurodegenerative conditions, including Alzheimer's disease and traumatic brain injury. The study found that inhibition of an enzyme called 15-PGDH was potently neuroprotective by restraining the production of reactive oxygen species that damage the brain.
A new PNAS special feature showcases the critical role of behavioral and decision sciences in U.S. governance, highlighting how psychological and economic research protect public health, consumer rights, and finances across federal agencies. The research demonstrates how 'invisible' scientific frameworks streamline medical drug reviews...
Researchers at the University of Warwick and Monash University have uncovered a molecular basis for combinatorial biosynthesis, a strategy to create multiple versions of powerful cancer therapies. By understanding how bacterial enzymes interact, they can design new therapies with improved potency and selectivity.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
A POSTECH research team has created an automated, modular system for assembling reconstituted cell-free systems, significantly reducing costs by 95% and preparation time to 2 days. This innovation enables the customization of individual components, paving the way for improved biologically engineered high-value therapeutics.
Researchers found that over-the-counter probiotics contain only 36 unique species of bacteria, with most common species being forms of Lactobacillus. The analysis suggests a lack of consistency in the combination of species used to support gut health and vaginal health claims.
A comprehensive analysis of 173,303 Pakistani genomes reveals the presence of 34,000 people with complete loss of function of at least one gene, known as 'human knockouts'. This study provides valuable information needed to develop new treatments for human diseases and sheds light on why drugs developed in mice often fail in humans.
Researchers at the University of Houston have discovered adding salt can help release therapeutic material from endosomes, improving delivery efficiency for mRNA vaccines and gene therapies. The simple strategy overcomes a major obstacle in gene medicine, potentially making these therapies more efficient and accessible worldwide.
Universities and hospitals conduct substantial numbers of late-stage clinical trials to repurpose generic drugs at reduced costs. This research has huge potential to provide society with affordable treatments for various conditions.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
Researchers found that temperature and calcium levels inside cells can dramatically impact how drugs interact with their targets. This discovery could lead to smarter medicine design and more effective treatments.
Researchers discovered a previously unknown binding site in a cancer-related protein that could lead to more precise cancer drugs. The study reveals the power and limitations of AI tools for drug discovery, showing that even small chemical changes can dramatically alter how molecules bind to proteins.
Researchers developed a miniaturized human intestine model to study EV-A71 infection, revealing the virus's ability to evade the immune system and persist for extended periods. The model showed long-term viral replication without triggering a strong immune response.
Scientists create a moiré metasurface to map right- and left-handed regions in materials, visualizing chirality as two-dimensional images. The new approach resolves chirality distributions with a resolution of approximately 100 μm.
Researchers at EPFL have discovered a way to generate and screen large libraries of synthetic cyclic peptides that can both enter cells and block disease-related protein interactions. This breakthrough could broaden access to previously difficult targets for drug development, enabling the creation of orally available peptide drugs.
Two projects, BOOST-HP and BIONIC, use machine learning to analyze large datasets of medication exposure and outcomes. The findings highlight the need for more data and cautious design of machine learning models to accurately assess potential links between medications and pregnant women.
Researchers at UW Medicine Institute for Protein Design and Skape Bio used AI methods to create on-demand molecules that can toggle GPCRs. The approach enables precise control of GPCR signaling in cells, offering new insights into bodily functions and potential medicines for diseases.
Researchers identified a vitamin K-dependent GAS6 pathway that controls osteoclast maturation and bone resorption in mice. Osteoblasts use Vitamin K signals to regulate osteoclast fusion via the GAS6 pathway.
The ISSCR Consortium supports the FDA's draft guidance on using new approach methodologies (NAMs) in drug development, emphasizing the need for a flexible and science-driven framework. The consortium recommends clarifying biological complexity alignment with context of use and expanding recognition of computational modeling and hybrid ...
Researchers used wastewater surveillance to detect drug-resistant Candida auris strains up to five months before patients showed symptoms, opening a new frontier for hospitals. The study found higher detection rates and concentrations of the pathogen in hospital wastewater compared to community-scale treatment plants.
Researchers have developed engineered peptide binders called CRABs that can selectively interfere with calcium signaling pathways, potentially leading to more effective and safer immunotherapies. The study's findings offer new hope for treating disorders linked to excessive CRAC-channel activity.
Researchers developed a new method called sm-PORE-cupine to study individual RNA molecules and reveal how their structures influence gene regulation. The technology provides deeper insight into how RNA structure affects cellular function and could help identify new therapeutic targets for diseases such as viral infections.
Researchers developed ApexGO, an AI-powered method to turn weak antibiotic candidates into more potent ones. The tool uses generative AI and Bayesian optimization to guide molecular tweaks, predicting which changes are likely to increase antimicrobial activity.
A PSU-led research team has developed a novel chemical compound, T111, that shows promise for treating and preventing malaria. The compound targets all three major life-cycle stages of the malaria parasite, making it a strong candidate for a single-encounter radical cure.
Researchers developed genESOM, a generative AI that can expand dataset volume and simulate larger animal numbers while maintaining reliability. This allows for 30-50% reduction in animal experiments without compromising results.
A team of researchers has uncovered a promising new target for antimalarial drug design, identifying an enzyme called aminopeptidase P from the Plasmodium falciparum parasite. The new inhibitors have been shown to bind more strongly and selectively than existing compounds, demonstrating potential as a new class of drugs to combat malaria.
The UK-led OpenBind initiative has released its first publicly available dataset and predictive AI model, accelerating the discovery of new medicines using artificial intelligence. The release showcases high-quality, standardized experimental data and a trained predictive model, enabling researchers worldwide to drive the next generati...
A multi-institutional team led by Sanford Burnham Prebys aims to develop a non-opioid pain therapeutic using lead molecule SBI-810. The effort, funded by a $3.9 million NIH grant, seeks to optimize the compound into a drug that could provide effective pain relief without addiction risks.
Researchers have developed a novel method to generate diazo compounds without toxic precursors, enabling efficient synthesis of valuable intermediates for chemical and pharmaceutical applications. The phosphine-mediated Michael addition reaction produces β-heteroatom-substituted diazo esters under mild conditions.
The FDA has merged two of OYE Therapeutics' Investigational New Drug applications, creating a more streamlined regulatory framework for development across related programs. This move is expected to improve regulatory efficiency, reduce duplicative development activity, and simplify operational execution.
Volume 39 of SLAS Discovery highlights novel assays and AI-assisted workflows to accelerate personalized cancer immunotherapy. The journal aims to advance life sciences discovery through education, knowledge exchange, and global community building.
A research consortium has developed mini-antibodies that can reactivate mutated p53, a key tumor suppressor protein. These DARPins bind selectively to p53 mutants, restoring stability and functionality, making them potentially useful against various types of tumors.
Chronic liver disease in the US costs $41.57 billion, with prescription medication expenditures accounting for nearly half of all-cause healthcare expenditures. Poor adherence to antiviral medications is a key factor in preventing disease progression and treatment, with high out-of-pocket costs increasing non-adherence risk.
Researchers at the University of East Anglia have discovered that light can be programmed using its natural geometry, allowing for the creation of structured light with unique properties. This breakthrough has far-reaching implications for fields such as medicine, data transmission, and quantum technologies.
The new facility enables scientists to observe and measure detonation forces in unprecedented detail, shedding light on industrial safety risks and potential breakthroughs. Researchers aim to develop safer designs and protocols by examining detonation disasters like the Buncefield Fire.
Dr. Dennis Slamon, a renowned breast cancer researcher, has been elected to the Association of American Physicians (AAP) for his pioneering work in HER2 gene discovery and targeted therapies. His research led to significant improvements in survival rates and established the principle of targeted cancer treatment.
A computational protocol has been established by University of Kent researchers to accurately identify reactions that can result in successful drug candidates for Chagas disease. This approach reduces the need for trial-and-error, prioritizing promising compounds earlier and making the drug discovery process faster and more affordable.
The experimental drug DH20931 targets triple-negative breast cancer by triggering a surge in fat-like molecules called ceramides, overwhelming cancer cells with toxic fats. In lab experiments, the drug made standard chemotherapy more effective, reducing the dose needed to kill cancer cells by about fivefold.
Researchers have discovered a way to prevent the collaboration between two important cancer-related proteins, N-MYC and Aurora A. This breakthrough could lead to new medications to combat childhood cancer. The study, published in Nature Communications, provides insights into how these proteins interact with each other.